Loading investment pitches...
Equity Research Database
Institutional Investment Pitches
Explore thousands of hedge fund pitches, high-conviction equity research memos, and portfolio manager commentary extracted from quarterly letters.
Explore thousands of hedge fund pitches, high-conviction equity research memos, and portfolio manager commentary extracted from quarterly letters.
Explore professional investment ideas sourced from institutional letters, short theses, and premium research channels, distilled into concise summaries.
| Pitch Type | Author | Industry | Pitch Thesis & Key Summary | Bull/Bear | Action | ||
|---|---|---|---|---|---|---|---|
| Sep 2, 2026 | Fund Letter | Neal KaufmanBaron Health Care Fund | BiotechnologyBiotechnology | Baron Health Care Fund - ARGX Biotechnology company argenx SE is best known for developing Vygart, the leading FcRn inhibitor for the treatment of autoimmune conditions. Shares rose after... | NEUTRAL | View Pitch → | |
| Jan 27, 2026 | Fund Letter | Neal KaufmanBaron Health Care Fund | BiotechnologyBiotechnology | Baron Health Care Fund 2025 Q4 (ARGX) Argenx SE is best known for developing Vyvgart, the leading FcRn inhibitor for the treatment of autoimmune conditions. Shares rose as... | BULL | View Pitch → | |
| Dec 3, 2025 | Fund Letter | Neal KaufmanBaron Health Care Fund | BiotechnologyBiotechnology | Artisan International Fund 2025 Q2 (ARGX BB) Argenx detracted in Q2 following weaker-than-expected demand for Vyvgart, its flagship therapy for generalized myasthenia gravis. Management cited slower... | BULL | View Pitch → | |
| Nov 28, 2025 | Fund Letter | Matt Kamm, Jason White, Jim Hamel, Angela Wu, Jay WarnerArtisan Mid Cap Fund | BiotechnologyBiotechnology | Artisan Mid Cap Fund 2025 Q3 (ARGX) Argenx's autoimmune therapy VYVGART® continues to deliver strong growth, driven by a subcutaneous formulation launch that allows self-administration. The company is... | BULL | View Pitch → |
Join institutional and professional investors receiving our weekly analysis of hedge fund letters, market trends, and high-conviction ideas.
Zero Spam • High Alpha • Unsubscribe Anytime
Investment pitches and theses displayed on Buyside Digest are summaries of opinions expressed in publicly available investor letters, research reports, or other commentary. These summaries are generated for informational and research purposes only and do not constitute investment recommendations, financial advice, or an endorsement of any particular security or strategy by Buyside Digest. Users should conduct their own independent due diligence and consult with professional advisors before making any investment decisions.